Dr. Mahtani on the Use of CDK 4/6 Inhibitors in Metastatic ER+ Breast Cancer

Reshma L. Mahtani, DO
Published: Friday, Mar 23, 2018



Reshma L. Mahtani, DO, assistant professor of clinical medicine, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses the use of CDK 4/6 inhibitors in older patients with estrogen receptor-positive breast cancer.

An FDA pooled analysis of the registration trials that led to the approval of CDK 4/6 inhibitors was presented at the 2017 San Antonio Breast Cancers Symposium. In the analysis, investigators looked at the studies with respect to age and treatment effect. Although CDK 4/6 inhibitors are very efficacious and pretty well tolerated, physicians wondered whether older patients could tolerate the medication as well as younger patients.

The use of CDK 4/6 inhibitors is something that should be considered in older patients, says Mahtani. Age should not be used as a reason not to administer these agents. Although there was an increased incidence of treatment discontinuation and increased grade 3/4 toxicity, the differences in select adverse events that are associated with the use of these therapies were not that great.
 


Reshma L. Mahtani, DO, assistant professor of clinical medicine, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses the use of CDK 4/6 inhibitors in older patients with estrogen receptor-positive breast cancer.

An FDA pooled analysis of the registration trials that led to the approval of CDK 4/6 inhibitors was presented at the 2017 San Antonio Breast Cancers Symposium. In the analysis, investigators looked at the studies with respect to age and treatment effect. Although CDK 4/6 inhibitors are very efficacious and pretty well tolerated, physicians wondered whether older patients could tolerate the medication as well as younger patients.

The use of CDK 4/6 inhibitors is something that should be considered in older patients, says Mahtani. Age should not be used as a reason not to administer these agents. Although there was an increased incidence of treatment discontinuation and increased grade 3/4 toxicity, the differences in select adverse events that are associated with the use of these therapies were not that great.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Community Practice Connections™: 1st Annual International Congress of Oncology Pathology™: Towards Harmonization of Pathology and Oncology StandardsAug 30, 20182.0
Publication Bottom Border
Border Publication
x